Published in Clin Infect Dis on January 06, 2014
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet (2015) 2.18
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07
Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study. Lancet Infect Dis (2014) 1.88
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment. BMJ Open (2016) 1.18
Challenges in managing HIV in people who use drugs. Curr Opin Infect Dis (2015) 1.13
Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus. Hepatology (2015) 1.10
Hepatitis C eradication: A long way to go. World J Gastroenterol (2015) 1.00
APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int (2016) 0.96
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Med (2016) 0.94
Access to hepatitis C medicines. Bull World Health Organ (2015) 0.93
Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol (2015) 0.91
Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries. BMC Infect Dis (2014) 0.90
Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. World J Gastroenterol (2015) 0.88
The use of generic medications for hepatitis C. Liver Int (2016) 0.88
Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability? J Clin Exp Hepatol (2014) 0.86
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Front Pharmacol (2016) 0.85
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy. Hepatology (2014) 0.85
Could international compulsory licensing reconcile tiered pricing of pharmaceuticals with the right to health? BMC Int Health Hum Rights (2014) 0.84
Highly divergent hepaciviruses from African cattle. J Virol (2015) 0.84
Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons. Ann Intern Med (2015) 0.82
Burden of substance use disorders, mental illness, and correlates of infectious diseases among soon-to-be released prisoners in Azerbaijan. Drug Alcohol Depend (2015) 0.82
Oxidative stress modulation in hepatitis C virus infected cells. World J Hepatol (2015) 0.81
Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago. PLoS One (2015) 0.81
Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. J Virus Erad (2015) 0.81
All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality. World J Hepatol (2015) 0.81
Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C. J Virus Erad (2016) 0.79
Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant. World J Hepatol (2015) 0.78
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Lancet Gastroenterol Hepatol (2016) 0.78
Functional foods effective for hepatitis C: Identification of oligomeric proanthocyanidin and its action mechanism. World J Hepatol (2014) 0.78
Hepatitis C: Treatment of difficult to treat patients. World J Hepatol (2015) 0.78
The Mechanism of Interferon Refractoriness During Hepatitis C Virus Infection and Its Reversal with a Peroxisome Proliferator-Activated Receptor α Agonist. J Interferon Cytokine Res (2015) 0.78
The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy. BMC Public Health (2016) 0.77
Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders. Dig Dis Sci (2016) 0.76
Molecular characterization of Hepatitis C virus 3a in Peshawar. BMC Infect Dis (2016) 0.75
Doing the math on hepatitis C virus treatment. J Hepatol (2016) 0.75
ReRouting biomedical innovation: observations from a mapping of the alternative research and development (R&D) landscape. Global Health (2016) 0.75
Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model. World J Hepatol (2016) 0.75
Exploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replication. Sci Rep (2016) 0.75
Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis. BMJ Open (2017) 0.75
Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy. J Clin Transl Hepatol (2016) 0.75
Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint. Trop Med Int Health (2016) 0.75
Trends in medicines procurement by the Brazilian federal government from 2006 to 2013. PLoS One (2017) 0.75
HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study. BMC Infect Dis (2016) 0.75
Hepatitis C cross-genotype immunity and implications for vaccine development. Sci Rep (2017) 0.75
Compulsory Licenses for Cancer Drugs: Does Circumventing Patent Rights Improve Access to Oncology Medications? J Glob Oncol (2016) 0.75
Willingness to use HIV pre-exposure prophylaxis among gay men, other men who have sex with men and transgender women in Myanmar. J Int AIDS Soc (2017) 0.75
Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation. J Pharm Policy Pract (2017) 0.75
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology (2013) 12.46
The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet (2006) 11.06
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature (2010) 8.95
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect (2011) 6.48
Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem (1972) 4.12
Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. JAMA (2010) 1.98
The global health burden of hepatitis C virus infection. Liver Int (2011) 1.80
Engineered in India--patent law 2.0. N Engl J Med (2013) 1.63
AIDS: patent rights versus patient's rights. Lancet (2000) 1.59
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother (2010) 1.49
A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries. Global Health (2011) 1.44
Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis (2012) 1.30
The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world. Lancet (2006) 1.24
Low-cost tools for diagnosing and monitoring HIV infection in low-resource settings. Bull World Health Organ (2012) 1.21
Treatment of hepatitis C as prevention: a modeling case study in Vietnam. PLoS One (2012) 1.09
Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother (2010) 1.05
Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335). J Med Chem (2010) 1.02
A brighter future in the fight against hepatitis. Nat Med (2013) 0.85
Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet (2002) 11.72
Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet (2006) 10.91
HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis (2010) 6.95
A systematic review of task- shifting for HIV treatment and care in Africa. Hum Resour Health (2010) 6.48
Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS (2010) 5.46
Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis (2007) 5.27
Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS (2006) 5.13
Technologies for global health. Lancet (2012) 5.05
25 years of the WHO essential medicines lists: progress and challenges. Lancet (2003) 4.95
Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med (2011) 4.68
HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis (2006) 4.56
The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis. BMJ (2011) 4.54
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS (2012) 3.50
Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis (2002) 3.46
Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS (2013) 3.17
Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med (2013) 3.15
Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review. J Int AIDS Soc (2012) 3.00
Distribution of antiretroviral treatment through self-forming groups of patients in Tete Province, Mozambique. J Acquir Immune Defic Syndr (2011) 2.97
Does ratification of human-rights treaties have effects on population health? Lancet (2009) 2.93
Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care. Trop Med Int Health (2010) 2.92
Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis (2013) 2.71
Stopping antiretroviral therapy. AIDS (2007) 2.63
Is operational research delivering the goods? The journey to success in low-income countries. Lancet Infect Dis (2012) 2.62
Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med (2012) 2.60
Expanding HIV care in Africa: making men matter. Lancet (2009) 2.54
Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis (2012) 2.45
Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime? Lancet (2008) 2.31
Antiretroviral treatment outcomes from a nurse-driven, community-supported HIV/AIDS treatment programme in rural Lesotho: observational cohort assessment at two years. J Int AIDS Soc (2009) 2.31
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24
Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics (2007) 2.24
Rational use of moxifloxacin for tuberculosis treatment. Lancet Infect Dis (2011) 2.21
Decentralising HIV treatment in lower- and middle-income countries. Cochrane Database Syst Rev (2013) 2.17
Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis (2013) 2.16
Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. PLoS One (2011) 2.11
Moxifloxacin for Buruli ulcer/HIV coinfected patients: kill two birds with one stone? AIDS (2013) 2.05
Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr (2010) 2.05
Mortality, violence and lack of access to healthcare in the Democratic Republic of Congo. Disasters (2003) 2.04
Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS (2012) 2.03
Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One (2013) 2.03
Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review. Trop Med Int Health (2011) 2.02
HIV treatment in a conflict setting: outcomes and experiences from Bukavu, Democratic Republic of the Congo. PLoS Med (2007) 1.94
Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax (2010) 1.91
Operative mortality in resource-limited settings: the experience of Medecins Sans Frontieres in 13 countries. Arch Surg (2010) 1.89
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis (2012) 1.89
Role and outcomes of community health workers in HIV care in sub-Saharan Africa: a systematic review. J Int AIDS Soc (2013) 1.82
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis (2009) 1.81
Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years. J Acquir Immune Defic Syndr (2011) 1.74
Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis (2012) 1.72
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals. J Acquir Immune Defic Syndr (2011) 1.71
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 1.68
Challenges and opportunities for the implementation of virological testing in resource-limited settings. J Int AIDS Soc (2012) 1.66
HIV infection and stroke: current perspectives and future directions. Lancet Neurol (2012) 1.66
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother (2006) 1.58
Community-supported models of care for people on HIV treatment in sub-Saharan Africa. Trop Med Int Health (2014) 1.58
Similar mortality and reduced loss to follow-up in integrated compared with vertical programs providing antiretroviral treatment in sub-saharan Africa. J Acquir Immune Defic Syndr (2012) 1.58
Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda. PLoS One (2011) 1.56
Surgical task shifting in Sub-Saharan Africa. PLoS Med (2009) 1.56
Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS (2011) 1.55
Feasibility of HIV point-of-care tests for resource-limited settings: challenges and solutions. BMC Med (2014) 1.51
Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS (2013) 1.49
HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Trans R Soc Trop Med Hyg (2008) 1.48
Viral load monitoring as a tool to reinforce adherence: a systematic review. J Acquir Immune Defic Syndr (2013) 1.46
Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda. J Int AIDS Soc (2011) 1.46
Lessons learned during down referral of antiretroviral treatment in Tete, Mozambique. J Int AIDS Soc (2009) 1.46
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies. J Acquir Immune Defic Syndr (2013) 1.46
When best practice is bad medicine: a new approach to rationing tertiary health services in South Africa. S Afr Med J (2008) 1.45
Community-based antiretroviral therapy programs can overcome barriers to retention of patients and decongest health services in sub-Saharan Africa: a systematic review. Int Health (2013) 1.42
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther (2008) 1.41
Expert reviews: who are they for? Expert Opin Pharmacother (2012) 1.39
The potential for interactions between antimalarial and antiretroviral drugs. AIDS (2005) 1.35
Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic. PLoS Med (2007) 1.33
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther (2010) 1.30
Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. AIDS (2007) 1.26
Antiretroviral therapy outcomes among adolescents and youth in rural Zimbabwe. PLoS One (2012) 1.26
Cesarean section rates and indications in sub-Saharan Africa: a multi-country study from Medecins sans Frontieres. PLoS One (2012) 1.25
Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges. Curr Opin HIV AIDS (2013) 1.23
Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations. Trans R Soc Trop Med Hyg (2005) 1.22
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis (2008) 1.22
An integrated approach of community health worker support for HIV/AIDS and TB care in Angónia district, Mozambique. BMC Int Health Hum Rights (2009) 1.21
Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural Lesotho. PLoS One (2011) 1.21
Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.21
Universal access: the benefits and challenges in bringing integrated HIV care to isolated and conflict affected populations in the Republic of Congo. Confl Health (2009) 1.21
Paediatric radiology seen from Africa. Part I: providing diagnostic imaging to a young population. Pediatr Radiol (2011) 1.19
Public health. Getting HIV treatment to the most people. Science (2012) 1.19
Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis (2011) 1.18
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Antivir Ther (2008) 1.17
British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med (2011) 1.17
Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother (2012) 1.17
Association of aging and survival in a large HIV-infected cohort on antiretroviral therapy. AIDS (2011) 1.16
The 2013 WHO guidelines for antiretroviral therapy: evidence-based recommendations to face new epidemic realities. Curr Opin HIV AIDS (2013) 1.14
Conflict in the Indian Kashmir Valley II: psychosocial impact. Confl Health (2008) 1.14
How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals. Drug Discov Today (2008) 1.14
Priorities for developing countries in the global response to non-communicable diseases. Global Health (2012) 1.13
Viral load monitoring in resource-limited settings: a medical and public health priority. AIDS (2012) 1.13
The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr (2003) 1.12
Trends in loss to follow-up among migrant workers on antiretroviral therapy in a community cohort in Lesotho. PLoS One (2010) 1.12
Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir Ther (2005) 1.12
Task shifting for the delivery of pediatric antiretroviral treatment: a systematic review. J Acquir Immune Defic Syndr (2014) 1.11